If trials are successful, TB-402 may reduce the risk of increased bleeding, a known side-effect of anticoagulants, and the need for regular blood coagulation monitoring.
-
ThromboGenics' TB-402 is a long-acting anticoagulant for treatment of VTE and... -
The long-half life of TB-402 may permit reduced dosing, giving it an... -
If trials are successful, TB-402 may reduce the risk of increased bleeding, a...
